Introduction

Capcitab 500 mg (Capecitabine) Tablet is an oral chemotherapeutic agent designed to treat colorectal cancer, breast cancer, and gastric cancer. Manufactured by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified leader in oncology therapeutics, and supplied globally by Onco Solution, this medication offers a convenient and targeted approach to cancer treatment. As a prodrug of 5-fluorouracil (5-FU), Capcitab 500 mg (Capecitabine) Tablet is enzymatically converted into its active form within the body, disrupting cancer cell proliferation through dual mechanisms of action.

Key Benefits & Mechanism of Action

Capcitab 500 mg (Capecitabine) Tablet works by mimicking natural cellular components to interfere with DNA and RNA synthesis in cancer cells. Its mechanism includes:

1. Conversion to 5-FU: Enzymes in the liver and tumor tissues metabolize capecitabine into 5-fluorouracil (5-FU), a potent antimetabolite.
2. Thymidylate Synthase Inhibition:
   • 5-FU is converted to FdUMP, which binds to thymidylate synthase (TS) along with folate cofactors, forming a stable ternary complex.
   • This inhibits the production of thymidine triphosphate (dTTP), a critical component for DNA replication, halting cell division.
3. RNA Disruption:
   • 5-FU is also metabolized into FUTP, which incorporates into RNA strands during synthesis.
   • This faulty RNA interferes with protein production and processing, leading to cancer cell death.

Clinical Applications & Indications

Capcitab 500 mg (Capecitabine) Tablet is approved for:

• Colorectal Cancer: First-line treatment for metastatic colorectal cancer, often combined with oxaliplatin (XELOX regimen).
• Breast Cancer: Monotherapy or combination therapy for advanced or metastatic HER2-negative breast cancer.
• Gastric Cancer: Adjuvant treatment for resected gastric cancer.

Why Choose Capcitab 500 mg (Capecitabine) Tablet?

• Oral Convenience: Avoids intravenous administration, enabling home-based treatment.
• Targeted Activation: Higher concentration of 5-FU in tumor tissues reduces systemic toxicity.
• Proven Efficacy: Demonstrated survival benefits in phase III trials for colorectal and breast cancers.
• Cost-Effective: Affordable alternative to IV chemotherapy, reducing hospital costs.
• Global Quality: Produced under WHO-GMP standards by Eskayef Pharmaceuticals Ltd.

Manufacturer Credibility

Eskayef Pharmaceuticals Ltd., part of Bangladesh’s Transcom Group, has delivered high-quality oncology therapies since 1990. Their state-of-the-art, WHO-GMP-certified facilities ensure Capcitab 500 mg (Capecitabine) Tablet meets stringent international safety and efficacy standards. With a legacy of innovation, Eskayef serves patients across Asia, Africa, and Europe. Learn more at www.skfbd.com.

Supplier Profile: Onco Solution

Onco Solution is a trusted global supplier committed to equitable access to cancer treatments like Capcitab 500 mg (Capecitabine) Tablet. Their services include:

• Bulk Procurement: Competitive pricing for hospitals and oncology centers.
• Global Supply Chain: Reliable delivery to 50+ countries, including underserved regions.
• Clinical Resources: Access to dosing guidelines and expert consultations via www.oncosolution.com.

Driven by innovation, integrity, and compassion, Onco Solution bridges gaps in cancer care by prioritizing affordability and education.

Technical Specifications

• Active Ingredient: Capecitabine 500 mg
• Dosage Form: Film-coated oral tablet
• Storage: Store below 25°C in a dry environment.
• Administration: Twice daily with food, as prescribed (typically 14-day cycles with 7-day rest periods).

Patient-Centric Advantages

• Flexible Dosing: Adjustable regimens to manage side effects like hand-foot syndrome or diarrhea.
• Reduced Hospital Visits: Oral administration supports outpatient care.
• Improved Compliance: Simplified dosing schedule compared to IV alternatives.

Clinical Efficacy & Safety

• X-ACT Trial: Demonstrated superior disease-free survival in stage III colon cancer vs. traditional 5-FU/leucovorin.
• RESPECT Trial: Showed efficacy in metastatic breast cancer with manageable toxicity.
• Common Side Effects: Diarrhea, hand-foot syndrome, fatigue, nausea.
• Severe Reactions: Myelosuppression, cardiotoxicity (rare).

Global Accessibility & Partnerships

Through collaboration with Eskayef Pharmaceuticals Ltd., Onco Solution ensures Capcitab 500 mg (Capecitabine) Tablet is supplied to low-resource regions, emphasizing:

• Affordability: Tiered pricing models for developing nations.
• Quality Assurance: Compliance with WHO-GMP, ISO, and FDA-equivalent standards.
• Education: Training programs for healthcare providers on side-effect management.

Ordering Information

Healthcare providers can procure Capcitab 500 mg (Capecitabine) Tablet via Onco Solution’s streamlined platform:

• Bulk Orders: Discounted rates for institutional buyers.
• Clinical Support: Guidance on dose adjustments and drug interactions.
• Global Network: Connect with oncology specialists at www.oncosolution.com.

Conclusion

Capcitab 500 mg (Capecitabine) Tablet redefines oral chemotherapy with its targeted efficacy and patient-friendly design. Trust Eskayef Pharmaceuticals Ltd. for uncompromised quality and Onco Solution for global supply. For orders or clinical inquiries, contact Onco Solution today.